4//SEC Filing
Vanover Kimberly E. 4
Accession 0001209191-19-002957
CIK 0001567514other
Filed
Jan 7, 7:00 PM ET
Accepted
Jan 8, 9:19 PM ET
Size
18.6 KB
Accession
0001209191-19-002957
Insider Transaction Report
Form 4
Vanover Kimberly E.
VP, Clinical Development
Transactions
- Exercise/Conversion
Common Stock
2019-01-04+1,554→ 37,224 total - Award
Restricted Stock Units
2019-01-08+58,915→ 58,915 total→ Common Stock (58,915 underlying) - Sale
Common Stock
2019-01-04$11.37/sh−7,380$83,911→ 29,844 total - Sale
Common Stock
2019-01-04$11.81/sh−2,184$25,793→ 27,660 total - Sale
Common Stock
2019-01-07$12.29/sh−592$7,276→ 27,068 total - Exercise/Conversion
Restricted Stock Units
2019-01-04−1,554→ 0 total→ Common Stock (1,554 underlying) - Award
Stock Option (right to buy)
2019-01-08+80,951→ 80,951 totalExercise: $12.73Exp: 2029-01-07→ Common Stock (80,951 underlying)
Footnotes (9)
- [F1]Restricted stock units convert into common stock on a one-for-one basis.
- [F2]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 4, 2018. The proceeds from these sales will be used primarily to cover the reporting person's tax liability arising from the vesting of restricted stock units.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.78 to $11.78, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.79 to $11.85, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.24 to $12.30, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
- [F6]Each restricted stock unit represents a contingent right to receive one share of common stock.
- [F7]On January 4, 2016, the reporting person was granted 4,661 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.
- [F8]On January 8, 2019, the reporting person was granted options to purchase 80,951 shares of common stock, vesting in three equal annual installments beginning on the first anniversary of the grant date.
- [F9]On January 8, 2019, the reporting person was granted 58,915 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.
Documents
Issuer
Intra-Cellular Therapies, Inc.
CIK 0001567514
Entity typeother
Related Parties
1- filerCIK 0001585669
Filing Metadata
- Form type
- 4
- Filed
- Jan 7, 7:00 PM ET
- Accepted
- Jan 8, 9:19 PM ET
- Size
- 18.6 KB